Press Releases

Select year

1/27/2023 Positive CHMP opinion for darolutamide in combination with docetaxel for the treatment of metastatic hormone-sensitive prostate cancer

1/26/2023 Orion publishes Financial Statement Release for 2022 on Thursday 9 February 2023

1/4/2023 Orion and Amneal enter strategic partnership – Orion receives exclusive licence to commercialise Amneal’s generic products in Europe, Australia and New Zealand

10/27/2022 Orion Research Foundation is awarding EUR 1 million in grants and two EUR 100,000 special grants today

10/6/2022 Orion publishes Interim Report for January–September 2022 on Thursday 20 October 2022

9/5/2022 Orion recalls Devisol Salmiakki dietary supplement from consumers

8/8/2022 U.S. FDA approves additional indication of darolutamide in combination with docetaxel for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC)

6/28/2022 Orion publishes Half-Year Financial Report for January–June 2022 on Friday 15 July 2022

5/9/2022 The negotiations under the Act on Co-operation within Undertakings concerning Orion’s R&D have been completed – future focus on pain and oncology

5/6/2022 Orion enters into exclusive agreement with Jemincare for novel non-opioid drug candidate for the treatment of pain

5/3/2022 U.S. FDA accepts supplemental new drug application (sNDA) and grants priority review for additional indication of darolutamide

4/22/2022 Orion’s collaboration partner Bayer submits application for additional indication of darolutamide in China

4/14/2022 Orion publishes Interim Report for January–March 2022 on Thursday 28 April 2022

3/24/2022 Orion is planning to refocus its R&D – in the future focus would be on cancer and pain

3/11/2022 Orion’s collaboration partner Bayer submits application for additional indication of darolutamide in Japan

3/9/2022 Orion’s collaboration partner Bayer submits applications in the U.S. and EU for additional indication of darolutamide

2/18/2022 Results from an Ongoing Phase I/II CYPIDES Trial of ODM-208 Presented at ASCO-GU

2/17/2022 Darolutamide plus androgen deprivation therapy and docetaxel significantly increases overall survival in patients with metastatic hormone-sensitive prostate cancer

1/20/2022 Orion publishes Financial Statement Release for 2021 on Thursday 10 February 2022

1/11/2022 Orion Corporation and CuraTeQ Biologics expand their biosimilar distribution agreement in Europe

11/11/2021 Orion Research Foundation grants 991,910 euros for research in 2022

10/5/2021 Orion publishes Interim Report for January–September 2021 on Wednesday 20 October 2021

8/18/2021 Orion Corporation and Alligator Bioscience announce immuno-oncology research collaboration and license agreement

8/17/2021 Orion will remain as the owner of pharmaceutical manufacturing plant in Kuopio, Finland

8/3/2021 Orion Corporation signs European wide marketing and distribution agreement with Marinus Pharmaceuticals for ganaxolone

7/12/2021 Orion recalls Multivita Forte dietary supplement from consumers

7/2/2021 Orion publishes Half-Year Financial Report for January–June 2021 on Monday 19 July 2021

6/21/2021 Orion Animal Health’s Tessie® (tasipimidine) receives positive CVMP opinion

6/9/2021 Orion’s Clinical Trial Shows Significant Improvement for Chronic Pain Patients Using Virtual Reality Therapy

6/8/2021 Orion and the Blood Service launch collaboration to develop new CAR T-cell cancer therapy

5/26/2021 Orion’s Virtual Capital Markets Day today at 13.00 EEST – presentation material now available

5/25/2021 Orion to investigate possible sale of its pharmaceutical manufacturing plant in Kuopio, Finland

5/17/2021 Orion Animal Health’s Bonqat® (pregabalin) receives positive CVMP opinion

5/4/2021 Invitation to Orion’s Virtual Capital Markets Day on 26 May 2021

4/27/2021 Orion aims to achieve carbon neutrality by 2030

4/12/2021 Orion publishes Interim Report for January–March 2021 on Tuesday 27 April 2021

3/15/2021 Save the date – Orion’s Virtual Capital Markets Day on 26 May 2021 at 1.00 p.m. – 4.00 p.m. EEST

2/8/2021 Orion and Bayer expand development program for darolutamide in prostate cancer

1/20/2021 Orion publishes Financial Statement Release for 2020 on Tuesday 9 February 2021

1/18/2021 Orion Animal Health and Vetoquinol expand collaboration – Vetoquinol to distribute Orion’s Clevor® in the USA and Orion to distribute Drontal® and Profender® products in Finland, Hungary and Romania

11/10/2020 Orion invests EUR 17 million in its production plants in Turku

11/4/2020 Orion Research Foundation grants 1 014 400 euros for research in 2021

10/19/2020 Orion's statutory co-operation negotiations completed regarding the Research & Development function

10/6/2020 Orion publishes Interim Report for January-September 2020 on Wednesday 21 October 2020

9/10/2020 Orion is planning to renew its R&D strategy and organisation

9/10/2020 New England Journal of Medicine publishes final overall survival data for darolutamide showing treatment significantly extends life in men with non-metastatic prostate cancer

6/26/2020 Orion publishes Half-Year Financial Report for January-June 2020 on Friday 17 July 2020

6/26/2020 Distribution of Zoetis’ products in Sweden, Denmark and Norway by Orion to end after 2020

6/4/2020 Orion is developing an immuno-oncology (IO) drug discovery platform in the national research and innovation consortium Cancer IO

5/20/2020 Sales of darolutamide started in the EU and Japan – Orion receives total of EUR 28 million milestones

5/14/2020 New ARAMIS Phase III data to be presented at ASCO 2020: Nubeqa® (darolutamide) significantly improved overall survival with a favorable safety profile in men with non-metastatic prostate cancer

4/14/2020 Orion publishes Interim Report for January-March 2020 on Tuesday 28 April 2020

3/30/2020 Nubeqa® (darolutamide) receives EU approval as a new treatment for men with non-metastatic castration-resistant prostate cancer

2/13/2020 Tero Närvänen is appointed Orion's new Vice President Quality Management as of 1 May 2020

1/31/2020 Positive CHMP opinion for darolutamide as a new treatment for men with non-metastatic castration-resistant prostate cancer

1/30/2020 Darolutamide plus androgen deprivation therapy significantly increased overall survival in men with non-metastatic castration-resistant prostate cancer

1/23/2020 Marketing authorization granted for darolutamide in Japan

1/22/2020 Orion publishes Financial Statement Release for 2019 on 5 February 2020

12/30/2019 Lotus to distribute Orion’s Stalevo® and Comtan® drugs in parts of Asia

12/9/2019 Orion presented data on oral levosimendan at the 30th International Symposium on ALS/MND

12/2/2019 Orion to present four posters on oral levosimendan in patients with ALS at the 30th International Symposium on ALS/MND

11/4/2019 Orion Research Foundation grants 902 000 euros for research in 2020

10/7/2019 Publishing of Orion Corporation's Interim Report for January-September 2019 on 23 October 2019

9/10/2019 Orion recalls Melatoniini Orion 1 mg Spray 20 ml oral spray from consumers

8/7/2019 Sales of darolutamide started in the USA – Orion receives EUR 45 million milestone

7/31/2019 U.S. FDA approves darolutamide, a new treatment for men with non-metastatic castration-resistant prostate cancer (nmCRPC)

7/15/2019 Orion completes enrollment in the REFALS Phase 3 trial studying the effect of oral Levosimendan in patients with amyotrophic lateral sclerosis (ALS)

6/27/2019 Publishing of Orion Corporation's Half Year Report for January-June 2019 on 17 July 2019

5/31/2019 2019 American Society of Clinical Oncology (ASCO) Annual Meeting - Darolutamide data presented

4/29/2019 U.S. FDA accepts New Drug Application for review and grants Priority Review for darolutamide

4/11/2019 Fire at Orion’s manufacturing plant in Turku

4/11/2019 Publishing of Orion Corporation's Interim Report for January-March 2019 on 25 April 2019

3/27/2019 Invitation to Orion's Capital Markets Day in Helsinki on Wednesday 22 May 2019

3/8/2019 Darolutamide submitted for European marketing authorization

3/5/2019 Darolutamide submitted for marketing authorization in Japan

2/27/2019 The rolling submission to FDA for darolutamide in the U.S. completed

2/14/2019 Orion's and Bayer's darolutamide shows substantial efficacy and a favourable safety profile in the treatment of prostate cancer in the ARAMIS trial

2/11/2019 Orion and Propeller Health partner to bring new digital medicines to people with asthma and COPD

2/5/2019 Orion and Bayer jointly present new data in prostate cancer from the Darolutamide ARAMIS -study

2/4/2019 Orion intents to start an open label extension study to the REFALS phase 3 trial studying the effect of oral levosimendan in patients with ALS

1/23/2019 Publishing of Orion Corporation's Financial Statement Release for 2018 on 6 February 2019

1/4/2019 Orion Corporation and Fifth Corner Inc join forces to research solutions for improving the quality of life of prostate cancer patients

12/4/2018 Orion acquires sales and distribution rights for certain European Countries for Parkinson's disease drug Stalevo

11/1/2018 Orion Research Foundation grants million euros for research in 2019

10/24/2018 Orion and Amgen to collaborate on the commercialisation of AMGEVITA® (biosimilar adalimumab) in Finland

10/10/2018 Publishing of Orion Corporation's Interim Report for January-September 2018 on 24 October 2018

9/17/2018 Creation of novel medicines and better patient care for the future in an ecosystem

9/10/2018 Johanna Ivaska has been appointed Head & Vice President of Oncology Research in Orion Corporation

7/6/2018 Orion has started a Phase III trial to develop a drug for ALS - The patient recruitment has begun

7/5/2018 Publishing of Orion Corporation's Half-Year Financial Report for January-June 2018 on 18 July 2018

6/14/2018 Fermion's new plant operational in Hanko - nearly 100% of production is exported

6/13/2018 Orion to join John Nurminen Foundation's Clean Baltic Sea projects as a new main partner

4/30/2018 Orion has completed the sale of Orion Diagnostica business division

4/10/2018 Publishing of Orion Corporation's Interim Report for January-March 2018 on 24 April 2018

4/3/2018 Status update of the Phase III ARAMIS clinical trial with darolutamide in patients with non-metastatic castration-resistant prostate cancer

3/19/2018 Orion has received positive conclusions for the salmeterol-fluticasone Easyhaler® combination under the EU's decentralized procedures

2/28/2018 Orion's statutory co-operation negotiations completed

1/24/2018 Publishing of Orion Corporation's Financial Statement Release for 2017 on 7 February 2018

1/4/2018 Orion to renew operating model of its laboratories

11/7/2017 Professor Heikki Joensuu has been appointed Vice President of Therapy area Oncology, R&D in Orion Corporation

10/12/2017 Publishing of Orion Corporation's Interim Report for January-September 2017 on 26 October 2017

10/5/2017 Orion receives Lean Prize 2016

9/22/2017 Orion Pharma scientists led research group wins award for study paper on dexmedetomidine oromucosal gel for noise anxiety in dogs

7/5/2017 Publishing of Orion Corporation's Half-Yearly Report for January-June 2017 on 19 July 2017

6/2/2017 Orion Diagnostica's co-operation negotiations in Oulu completed

5/18/2017 Orion Capital Markets Day 2017 today 18 May 2017 in Helsinki

5/16/2017 Välittämö100 Web service enables you to donate to carers and their families

4/6/2017 Orion Diagnostica initiates co-operation negotiations concerning 14 persons in Oulu

3/16/2017 Invitation to Orion's Capital Markets Day in Helsinki on May 18, 2017

2/10/2017 Orion Research Foundation grants EUR 1 million for research

1/27/2017 Reijo Salonen, Senior Vice President, Pharmaceutical R&D, is CTO of the Year 2017

12/21/2016 Orion is planning to apply for a marketing authorisation for combined salmeterol-fluticasone formulation of the Easyhaler® product family

12/14/2016 Orion and University of Wisconsin-Madison will start strategic collaboration

9/2/2016 Orion Corporation and Menarini Group collaborate on budesonide-formoterol Easyhaler® combination product for asthma and COPD

6/22/2016 Orion Corporation and Asahi Kasei enter into global strategic collaboration

3/11/2016 Fermion invests in a new production facility in Hanko

3/7/2016 The German Center for Neurodegenerative Diseases and Orion Corporation start strategic collaboration

12/3/2015 Orion has developed Sileo® product to alleviate noise anxiety in dogs - marketing authorisation in the EU area

12/2/2015 Controlling medication risks with a new drug category - Finns want simple pain relief

11/25/2015 No foreign capsules detected in packages of Orion's Burana-Caps

11/24/2015 Orion recalls Burana-Caps 400 mg capsules from pharmacies and consumers as a precaution

8/13/2015 Kaisa Tarkkanen has been appointed as President of Orion Diagnostica Oy as of 1 October 2015

4/13/2015 Invitation to Orion's Capital Markets Day on 26 May 2015

3/26/2015 Orion signs cooperation agreement with HUCH Comprehensive Cancer Center

3/3/2015 Save the Date: Orion Corporation's Capital Market Day in Helsinki on 26 May 2015

2/5/2015 Orion Pharma Animal Health and Vetoquinol enter into distribution collaboration as of 1 January 2015

11/18/2014 Arto Toivonen has been appointed as President of Fermion Oy as of 1 January 2015

10/2/2014 Orion is campaigning in pink for girls

4/14/2014 ODM-201 offers a new therapeutic option for the treatment of prostate cancer

3/21/2014 Orion's pharmaceutical plant opens in Salo - investment will create over 100 jobs

2/3/2014 The androgen receptor inhibitor ODM-201 - New insights in the treatment of prostate cancer

12/17/2013 Orion Diagnostica Oy and Eurofins Medigenomix enter into a license agreement on Orion Diagnostica Oy's proprietary SIBA® technology

10/22/2013 Orion licenses the levosimendan injection rights in the USA and Canada to Phyxius

9/28/2013 Encouraging results from a clinical Phase II trial of ODM-201 for advanced prostate cancer (ARADES Trial)

3/21/2013 Orion Corporation presented promising Phase II data for new Parkinson's disease drug at AAN Annual Meeting

3/21/2013 Orion Corporation presented promising Phase II data for new Alzheimer's disease drug at AAN Annual Meeting

3/12/2013 Orion Corporation and Gedeon Richter signed novel CNS R&D collaboration agreement

2/15/2013 Promising preclinical and Phase I data of a new generation androgen receptor (AR) inhibitor, ODM- 201, presented at ASCO GU 2013 symposium

10/30/2012 Results of independent analyses show that Orion's DeviSol preparation meets its requirements

10/25/2012 Orion planning new packaging and logistics centre - new jobs in Salo

10/23/2012 Orion receives positive Phase II study results of a new levodopa product for Parkinson's disease

9/30/2012 Phase I/II ARADES trial of a new generation anti-androgen, ODM- 201, presented at ESMO 2012 congress

9/21/2012 Researcher Hannes Lohi receives an award worth EUR 75,000 - Canine genetic research also helps understand human diseases

3/22/2012 Orion's MIDEX and PRODEX results published in JAMA

12/21/2011 Production restarts at Orion's manufacturing plant in Turku after the fire in November

11/22/2011 Fire stops production at Orion's manufacturing plant in Turku

10/5/2011 Orion Corporation introduces new intensive care sedative Dexdor®

8/4/2011 Orion Corporation and Nycomed to collaborate on Easyhaler® for asthma and COPD

1/28/2011 Orion Corporation and Endo Pharmaceuticals enter into novel R&D collaboration

6/15/2009 Reijo Salonen receives the title of Professor

6/25/2008 Orion's marketing rights for Paclical® Vet (paclitaxel) expanded European-wide

5/30/2008 Orion receives rights for incontinence drug Kentera® from Recordati

4/4/2008 Orion receives European rights from Indevus for Vantas®, for prostate cancer

12/28/2007 Orion-Farmos Tutkimussäätiö jakaa 50-vuotisjuhlansa kunniaksi tutkimukseen 0,65 miljoonaa euroa

5/29/2007 Orion introduces a medicine for treating obese dogs

10/31/2006 New evidence demonstrates early use of Stalevo improves quality of life and may provide long-term benefits in patients with Parkinson's disease

10/10/2006 Management change in Orion's Communications